Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
Catumaxomab (Removab®) has not been endorsed for use within NHS Wales for the treatment of malignant ascites. The holder of the marketing authorisation is not in a position to progress a submission to AWMSG for the appraisal of catumaxomab (Removab®) for the above indication. As a result, AWMSG cannot provide advice to the Minister for Health and Social Services. |
||
|
||
Medicine details |
||
| Medicine name | catumaxomab (Removab®) | |
| Formulation | 10 mg and 50 mg concentrate for solution for infusion | |
| Reference number | 374 | |
| Indication | Treatment of malignant ascites |
|
| Company | Fresenius Biotech GmbH | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 20/08/2009 | |